General Oncology is developing targeted therapies for solid metastatic cancers and hematological malignancies, focusing on patients with inherited BRCA1, BRCA2, or PALB2 mutations. Their clinical and preclinical pipeline aims to provide effective treatment options that address the high mortality rates associated with these aggressive cancer types.
Funding
$7.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Metastatic cancers and hematological malignancies, particularly those associated with inherited BRCA1, BRCA2, or PALB2 mutations, often exhibit aggressive behavior and high mortality rates, necessitating more effective treatment options.
Solution
General Oncology is a pharmaceutical company dedicated to developing targeted therapies and comprehensive treatments for metastatic cancers and hematological malignancies. Their primary focus is on cancers arising in individuals with inherited BRCA1, BRCA2, or PALB2 mutations. The company's pipeline includes clinical and preclinical studies aimed at designing novel cancer drugs and methods for the cure of metastatic cancer. Their lead treatment has reached the clinical trial phase.
Target Audience
The primary target audience includes patients with solid metastatic cancers and hematological malignancies, specifically those with inherited BRCA1, BRCA2, or PALB2 mutations.
Features
- Pipeline of investigational cancer treatments for solid tumors and blood cancers.
- Focus on developing drugs for metastatic cancers associated with BRCA1, BRCA2, or PALB2 mutations.
- Unique approach to designing new cancer drugs and comprehensive treatments.